Autologous T cells are engineered to express a chimeric antigen receptor that recognizes EX02 on tumor cells, enabling MHC-independent binding and activation of the T cell. CAR engagement triggers T‑cell activation, proliferation, cytokine release, and cytotoxic killing (e.g., perforin/granzyme) of EX02‑positive cancer cells. Administered intratumorally or intraperitoneally (with optional IV after lymphodepletion) to enhance expansion and persistence.